Infectious Disease Connect Combines with US Merck's ILAsM Health Solutions.

MANews-(C)2009-2020

US-based drugmaker Merck's (NYSE: MRK) ILAsM Health Solutions has combined with Infectious Disease Connect Inc., a University of Pittsburgh Medical Center-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, to support infectious disease management, clinical decision-support and precision antibiotic therapy, Merck said.

As part of this agreement, UPMC Enterprises, the innovation and commercialisation arm of UPMC, and Merck Global Health Innovation Fund each are investing USD 5m to support development of customer offerings and business growth for the newly combined entity.

UPMC will retain a majority stake in the combined company.

Infectious Disease Connect has established a telemedicine solution for infectious disease care enabling doctors to access the expertise of an infectious disease specialist to facilitate timely diagnosis and treatment of patients under their care.

With ILAsM's platform, physicians and pharmacists will receive real-time antimicrobial usage and resistance data from partner hospitals to help them select appropriate therapy, while managing costs, toxicity and the potential for further resistance and transmission of infection.

ILAsM uses machine learning to evaluate a patient's demographic factors, medication history, past hospitalizations and other data to generate individualised treatment recommendations.

ILAsM also has developed a public health surveillance platform in conjunction with the New York State Department of Health to track and limit the spread of drug-resistant organisms and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT